Natera Inc., a cell-free DNA and precision medicine company, has acquired Foresight Diagnostics, a leader in ultrasensitive ...

An Austin, Texas-based genetics-testing company that specializes in cell-free DNA and precision medicine has acquired Foresight Diagnostics Inc., a Boulder-based cancer-diagnostics company.

Researchers have discovered that analyzing specific patterns of cell-free DNA (cfDNA) fragmentation in a simple urine sample ...

The treatment success rate for cancer patients improves when doctors detect the disease during its initial stages, because ...

A novel blood test analyzing fragments of cell-free DNA showed robust diagnostic performance for colorectal cancer across clinical subgroups, offering a promising noninvasive screening method.

A closeup look at colibactin’s structure reveals chemical motifs that guide its mutation-wreaking “warheads” to specific stretches of DNA.

Researchers have discovered that analyzing specific patterns of cell-free DNA (cfDNA) fragmentation in a simple urine sample ...

A Europe-focused study published in the journal Science examined 87 ancient and modern cat genomes and found that the domestic cat, which has the scientific name Felis catus, originated in North ...

Roche is investing $75 million in Freenome as part of the deal, which comes a year after the Swiss company led a $254 million financing round.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced the publication of more than 300 peer-reviewed papers featuring its technology and ...

Over 150 publications featuring Natera’s oncology portfolio, with more than 140 focused on the utility of Signatera™ across multiple types of cancer. More than 100 publications on its Women’s Health ...

Please provide your email address to receive an email when new articles are posted on . Biopsies with high donor-derived cell-free DNA levels were likely to reveal antibody-mediated rejection.